Arbutus Biopharma (ABUS) announced its 2025 corporate objectives and provided a financial update. The Company had cash, cash equivalents and investments in marketable securities totaling ...
Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report), retaining the price target of $5.00. Discover outperforming stocks and invest ...
Arbutus Biopharma stock opened at $3.21 on Tuesday. The business has a fifty day moving average price of $3.41 and a 200-day moving average price of $3.72. The stock has a market capitalization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback